Estradiol Patch Shortage: Why Are Women Still Hunting for Hormones?

Women who rely on estrogen patches to control hot flashes, night sweats and other symptoms of menopause have been discovering something disappointing at the pharmacy: their medicine may be unavailable. The estradiol patch shortage is still causing problems in the United States and elsewhere, despite an extraordinary increase in production. The FDA says manufacturers have roughly doubled the supply of estradiol patches during the last year. Apparently, even that hasn’t been enough to keep up with rapidly growing demand.

This question appeared this week in our nationally syndicated newspaper column. The author wondered what caused the estradiol patch shortage:

Q. Do you know why there has been a shortage of estradiol patches for months? Is this a nationwide problem? Are there any workarounds?

A. The Food and Drug Administration removed a scary warning about hormone replacement therapy in 2025. Demand for estradiol patches subsequently surged. The FDA says manufacturers have nearly doubled their output, but drug companies are still struggling to keep up.

Your physician and pharmacist may be able to help by locating a different formulation that would work for you.

That was the short answer for newspaper readers. You get a more nuanced and complete answer here on our website.

The Estradiol Patch Shortage Is Still Real

There is an odd discrepancy in the way government agencies and professional organizations describe the current situation.

The American Society of Health-System Pharmacists (ASHP) still lists estradiol transdermal systems as an active drug shortage. Its shortage database identifies products from Amneal, Noven, Sandoz, Viatris and Zydus that are backordered, on allocation or being released intermittently. Some manufacturers cannot even provide an estimated date for full resupply.

The most recent summary from ASHP up to September 2026 states:

• “Shortages due to increased demand, such as estradiol transdermal patches, result in patients going without treatment.”

The FDA takes a somewhat different position.

On October 30, 2026, Health and Human Services announced:

“The Agency is in close contact with manufacturers of all FDA-approved MHT [menopausal hormone therapy] formulations and, based on current information, is not aware of an imminent risk of a nationwide shortage. In addition, FDA continues engaging with all six manufacturers of FDA-approved estradiol transdermal patches to address access challenges driven by a significant rise in demand. Manufacturers have and continue to actively scale up, with measures including expanded production capacity, additional manufacturing shifts, and prioritized output of estradiol patch products. These efforts have resulted in an overall doubling of market output in the last 12 months. Patches are only one option for treatment, and FDA continues to monitor supply for other dosage forms, such as gels and creams.”

But in the very same announcement, the agency acknowledged:

“FDA has heard directly from patients and consumers who have reported localized challenges in finding their usual MHT products, and we take those reports seriously. Women who are having difficulty finding their usual patch product are encouraged to speak with their pharmacist or healthcare provider, who may be able to identify an available alternative or equivalent option appropriate for their individual needs.”

Translation: there may be enough patches somewhere in the country, but that doesn’t help very much if your dose and your brand are unavailable at your pharmacy.

This is not exclusively an American problem.

Australia’s Therapeutic Goods Administration, roughly the country’s equivalent of the FDA, states explicitly that the “ongoing shortage of HRT patches is global.” Several Estradot strengths remain in limited supply there, with shortages expected through December 31, 2026. Australia has gone so far as to permit importation of overseas products and allow pharmacists to substitute certain brands or strengths without obtaining a new prescription.

And on October 28, 2026, Health Canada designated estrogen transdermal patches as a Tier 3 drug shortage, the country’s category for shortages with the greatest potential health-system impact.

So yes, something very real is going on!

What’s Causing the Estradiol Patch Shortage?

The biggest culprit appears to be astonishingly rapid growth in demand. Manufacturers have added production shifts, enlarged batches, expanded manufacturing capacity and installed specialized equipment. But demand has been growing even faster.

An analysis of IQVIA prescription data by the Association for Accessible Medicines found that dispensed estrogen-patch prescriptions doubled from approximately 1.8 million in January 2025 to 3.6 million in June 2026. That is a staggering change in a year and a half.

The FDA believes its own change in hormone-therapy policy contributed to the surge. In November 2025 the agency asked manufacturers to revise longstanding boxed warnings for menopausal hormone therapy. Then, on February 12, 2026, FDA approved revised labeling for six products. Warnings about cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning for these products.

The FDA now says demand increased following that policy change. That certainly does not prove that every additional prescription resulted from the labeling decision. Menopause has also received enormously increased public attention in recent years. The timing of the dropped warnings and the beginning of shortages is striking, however.

Why Can’t Drug Companies Just Make More Patches?

Making an estradiol patch isn’t quite like stamping out another batch of tablets. Transdermal drug-delivery systems require specialized manufacturing equipment, adhesives, membranes or drug-containing matrices and sophisticated quality control. The patch has to adhere to the skin and release approximately the right amount of estradiol hour after hour for days.

FDA specifically notes that increasing patch production can take time because of the specialized equipment and manufacturing processes involved.

Australia reports another wrinkle. Manufacturing problems with some products have forced patients toward competing brands, increasing demand for those products and creating a kind of pharmaceutical domino effect.

That helps explain how manufacturers can double production and still struggle to keep pharmacies stocked.

Estradiol Patch Shortage: What Can You Do?

First, don’t assume that “out of stock” means there are no estradiol patches available anywhere.

Ask the pharmacist to check:

• another manufacturer of the same strength,
• a nearby pharmacy,
• a different chain or independent pharmacy,
• a therapeutically appropriate once-weekly or twice-weekly product, or
• another strength that your prescriber could use to construct an equivalent regimen.

Availability can differ dramatically according to brand, dose, pharmacy and geography. The FDA specifically recommends asking pharmacists to locate another FDA-approved estradiol transdermal patch when appropriate.

There is one workaround we would not recommend improvising: cutting a patch. ASHP warns that although some estradiol patches use a matrix system, cutting them can lead to unpredictable drug delivery and stability. Reservoir patches should never be cut. Australia’s drug regulator also advises patients not to cut estradiol patches to make up another dose.

If two lower-strength patches are to be substituted for one higher-strength patch, that decision should be made by the pharmacist or prescriber rather than through home experimentation.

Could a Gel Replace a Patch During the Estradiol Patch Shortage?

Possibly. Systemic estradiol comes in several forms, including patches, gels, sprays and pills. But here’s an important point that is often overlooked:

“Topical” does not mean “local.”

An estradiol patch is applied to the skin, but its whole purpose is to transport estradiol through the skin and into the bloodstream. Estradiol gels work the same basic way. They are systemic hormone therapy. That’s very different from putting a topical antibiotic on a scrape with the expectation that very little will enter the circulation.

The Transdermal Route Does Matter, Though

Oral estrogen passes first through the liver. Transdermal estrogen largely avoids this “first-pass” liver effect.

A large Danish study (BMJ September 23, 2026) compared contemporary forms of menopausal hormone therapy. Oral estrogen was associated with increased rates of venous thromboembolism [blood clots], ischemic stroke and myocardial infarction [heart attacks]. Transdermal therapy was not associated with an increased overall rate of those thrombotic events, with one exception involving a particular combined cyclic regimen.

That is an important reason why simply switching someone from a patch to an estrogen pill may not be an insignificant change.

Does Transdermal Estrogen Still Have Risks?

Yes. Avoiding the liver’s first-pass metabolic effect may reduce the risk of blood clots compared with oral estrogen, but an estradiol patch is still delivering a biologically powerful hormone throughout the body.

The newest Cochrane review on long-term menopausal hormone therapy, published September 4, 2026, concluded that risk depends substantially on whether treatment consists of estrogen alone or estrogen combined with a progestogen. Estrogen-only therapy probably increases stroke and gallbladder disease while reducing fractures. Combined hormone therapy (estrogen + progestogen) probably increases breast cancer risk and may increase thromboembolism. Here is a link to the actual systematic review from the Cochrane Database so you can read it for yourself.

The authors also emphasize an important limitation: much of the randomized evidence comes from older oral regimens and may not perfectly represent today’s transdermal estradiol preparations. I find it outrageous that we do not have large, long-term hormone studies of estrogen alone or estrogen plus progesterone.

We have much better randomized evidence for older oral hormone therapy than we do for many of today’s “bioidentical” transdermal regimens. Many women and their healthcare providers assume that bioidentical hormones are far safer than so-called “synthetic” formulations. If that is your perspective, please take a few minutes to listen to last week’s podcast with a brilliant breast cancer specialist:

Carey K. Anders, MD, FASCO, is Professor of Medicine in the Division of Medical Oncology at Duke University Health System. She is Director of the Duke Center for Brain and Spine Metastasis, Associate Director of Clinical Research at the Duke Cancer Institute & Duke University Health System.

Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

Estrogen, Progesterone and Breast Cancer

This is where the hormone story becomes especially complicated. The Women’s Health Initiative actually conducted two different randomized trials. Women who had undergone hysterectomy received conjugated equine estrogen (Premarin) alone. Women who still had a uterus received conjugated equine estrogen plus the synthetic progestin medroxyprogesterone acetate (Prempro).

Long-term follow-up published in JAMA (July 28, 2020) found strikingly different results.

Among women who had undergone hysterectomy, estrogen alone was associated with lower breast cancer incidence and lower breast cancer mortality than placebo during long-term follow-up. But among women who received estrogen plus medroxyprogesterone acetate, breast cancer incidence was higher.

That does not mean estrogen alone is automatically “safe.” Nor does it prove that natural micronized progesterone has the same breast-cancer risk as medroxyprogesterone acetate. In fact, a 2026 review concludes that micronized progesterone may have a more favorable breast and cardiovascular safety profile than some synthetic progestins. But the authors stress that the randomized evidence necessary to establish this conclusively is lacking.

That’s an important distinction. We should not automatically transfer every risk discovered with Prempro to every modern estradiol-plus-progesterone regimen. But neither should we assume that “bioidentical” means harmless.

Why Do Women with a Uterus Usually Need a Progestogen?

Estrogen stimulates the lining of the uterus. Giving systemic estrogen without adequate opposition can cause endometrial hyperplasia and ultimately increase the risk of endometrial cancer. That problem was recognized decades ago. A progestogen is generally added to systemic estrogen therapy in women with an intact uterus to protect the endometrium.

That protection comes with its own complicated tradeoffs. The long-term Women’s Health Initiative follow-up found that conjugated estrogen plus medroxyprogesterone acetate actually reduced endometrial cancer incidence compared with placebo.

On the other hand, the combined regimen increased breast cancer incidence (Journal of Clinical Oncology, Oct. 20, 2024). The same study produced another surprising finding: among women who had undergone hysterectomy, estrogen alone was associated with roughly twice the incidence of ovarian cancer compared with placebo, although the absolute numbers were small: 35 cases versus 17 during long-term follow-up.

By now, you are probably recognizing that hormones rarely provide simple yes-or-no answers.

What About Vaginal Estrogen? Is It Really “Local”?

Here we need to distinguish low-dose vaginal estrogen from an estrogen patch or gel. Low-dose vaginal estrogen is intended primarily to treat the genitourinary syndrome of menopause: vaginal dryness, painful intercourse, irritation and some urinary symptoms. It is not generally a substitute for systemic estrogen when the problem is hot flashes or night sweats.

And although vaginal estrogen is often called “local,” it is not correct to say that none of the hormone reaches the bloodstream. Estradiol can cross vaginal tissue.

The current FDA prescribing information for Estring, for example, reports an initial rise in blood estradiol after insertion. With continued use, average levels are quite low and generally remain within the range seen in untreated postmenopausal women. The manufacturer estimates that roughly 8 percent of the estradiol released daily by Estring is absorbed systemically.

A pharmacokinetic review reached a similar conclusion: systemic absorption from low-dose vaginal estrogen is generally very low, but it varies with the dose, formulation and even where the medicine is placed in the vagina. So “minimal systemic absorption” is scientifically defensible. “Zero systemic absorption” is not.

Does Vaginal Estrogen Carry the Same Cancer Risk?

The evidence is reassuring, particularly for low-dose vaginal therapy. The European Code Against Cancer, 5th edition, published in Molecular Oncology in January 2026, reviewed the evidence on hormone therapy and cancer. Its authors concluded that systemic HRT is associated with increased breast cancer risk in observational studies, particularly combination therapy, but made an important exception for vaginal estrogen.

They reported that vaginal estrogen has not been associated with increased breast cancer risk.

Even among breast cancer survivors, emerging evidence is reassuring. A review published in JCO Oncology Practice in October 2026 found minimal systemic absorption with low-dose vaginal formulations and no clear increase in breast cancer recurrence or mortality in observational studies and meta-analyses.

The authors did, however, urge greater caution for women taking aromatase inhibitors because the evidence in that population is more limited. That is quite different from claiming that vaginal estrogen cannot possibly have systemic effects.

The Estradiol Patch Shortage Shouldn’t Force Hasty Decisions

Menopause can be miserable. For some women, hot flashes and night sweats are not minor annoyances. They can wreck sleep, impair concentration, interfere with work and substantially diminish quality of life. Hormone therapy remains the most effective treatment we have for such “vasomotor” symptoms.

The modern evidence also suggests that route, dose, age, timing and type of progestogen matter. A healthy 52-year-old woman five years after menopause considering low-dose transdermal estradiol is in a very different situation from a 72-year-old woman beginning systemic hormone treatment two decades after menopause.

A 2026 review of menopausal hormone treatment concludes that women younger than 60 or within approximately 10 years of menopause generally have a more favorable benefit-risk balance, provided individual cardiovascular, clotting and cancer risks are considered.

Final Words

What we don’t want is for an estradiol patch shortage to turn an individualized medical decision into a frantic scavenger hunt followed by an improvised substitution. If your usual patch disappears, talk first with the pharmacist and prescriber. Another manufacturer, dose or patch schedule may solve the problem. A transdermal gel or spray may sometimes be appropriate.

Oral estrogen may also be an option, but it does not necessarily carry the same clotting-risk profile as transdermal estradiol. And vaginal estrogen is generally not an equivalent substitute for systemic hormone therapy when the goal is controlling hot flashes and night sweats.

One final thought: the FDA’s decision to soften hormone warnings represents an important reassessment of decades-old evidence. But removing a boxed warning should not be interpreted as declaring hormones harmless.

Estrogen and progesterone are among the most powerful signaling molecules in the human body. They can dramatically improve quality of life. They can also alter risks for blood clots, stroke and certain cancers, depending upon the hormone, dose, route, duration and the individual woman taking it.

That’s why the current shortage is more than an inventory problem. Women deserve both reliable access to their medicine and reliable information about its benefits and risks.

You may find these articles helpful for learning more about HRT:

“Why Is Hormone Replacement Therapy So Controversial?“

Estrogen and Breast Cancer: Yes–NO!–Maybe?

Please share your own experience with menopausal hormone therapy in the comment section below. Thank you for supporting our work.